Healthcare companies (device manufacturers, payors, and providers, among others) have long relied on technology as a core utility—for tracking R&D efforts and patient information, scheduling payments and services, launching new care options, and generally keeping the lights on.
Look out Silicon Valley, there’s a new innovation hotbed in town.
For the second year in a row, Central Texas Angel Network (CTAN) has won the coveted #1 ranking at the Angel Capital Association’s annual ACA Summit in San Francisco.
AstraZeneca (LSE: AZN) and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Imfinzi (durvalumab). Imfinzi is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (mUC) who have disease progression during or following platinum-containing chemotherapy, or whose disease has progressed within 12 months of receiving platinum-containing chemotherapy before (neoadjuvant) or after (adjuvant) surgery. Imfinzi is approved under the FDA’s accelerated approval pathway, based on tumour response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.
Tired of seeing most of the $1 billion-plus it raised for startup funding leave the state, Johns Hopkins University has opened a new state-of-the-art technology incubation hub, part of a $65 million expansion project.
If there was any doubt that a Republican-led Congress might give a strong boost to federal science spending, the Trump administration probably sealed the deal.
With its call in March for a mammoth $6-billion cut in the annual budget of the National Institutes of Health, the administration appears to have done more than anything else to energize the science community and supportive lawmakers, advocates said.
NHLBI small business awardees are eligible to apply for a competing revision to your current award. The Regenerative Medicine Innovation Project (RMIP), will support revision projects that propose solutions to widely recognized issues in the development of safe and effective regenerative medicine therapies.
Awards are anticipated in FY 2017
GSK today announced $139 million of new investment in its biopharmaceutical manufacturing site in Rockville, MD to support growing demand for BENLYSTA® (belimumab) for adult patients with active, autoantibody-positive, systemic lupus erythematosus (SLE) who are receiving standard therapy.
The National Institutes of Health will get a $2 billion funding boost over the next five months, under a bipartisan spending deal reached late Sunday night in Congress. The agreement marks a sharp rejection of President Trump’s proposal to cut $1.2 billion from the medical research agency in the current fiscal year.
For Charles Li, locating his office at the Johns Hopkins University Montgomery County Campus is like coming home.
Li received his MBA from the Carey Business School in 2014 and took the majority of his classes at the Rockville campus. Three years later, when presented with the opportunity to open a business office in Maryland, he chose JHU MCC. He likes the campus library and the proximity to his house.
Cerecor Inc. (NASDAQ: CERC), a clinical-stage biopharmaceutical company developing treatments to make a difference in the lives of patients with neurological and psychiatric disorders, today announced topline clinical results from a small, proof-of-concept clinical trial sponsored by the National Institute of Mental Health (“NIMH”) of the National Institutes of Health. This was a Phase 2 trial of CERC-501, a potent and selective oral kappa opioid receptor (“KOR”) antagonist, in treatment resistant depression (“TRD”) conducted under the leadership of Dr. Maurizio Fava of Massachusetts General Hospital (“MGH”).
